hackint0sh/temp-data huggingface dataset:
protocolSection identificationModule nctId: NCT06366932, orgStudyIdInfo id: DermAtOmics-II, briefTitle: Optimization of Atopic Dermatitis Treatment That Requires Second-line Systemic Therapy Through Predictive Models, statusModule overallStatus: RECRUITING, startDateStruct date: 2023-09-25, primaryCompletionDateStruct date: 2025-09, completionDateStruct date: 2025-09, studyFirstPostDateStruct date: 2024-04-16, lastUpdatePostDateStruct date: 2024-04-16, sponsorCollaboratorsModule leadSponsor name: Instituto de Investigación Hospital Universitario La Paz, class: OTHER, descriptionModule briefSummary: This is a low-intervention phase IV trial. The main objective is to optimize the treatment of patients with moderate-severe atopic dermatitis that require systemic treatment after failure, intolerance or contraindication to cyclosporine., conditionsModule conditions: Atopic Dermatitis, designModule studyType: INTERVENTIONAL, phases: PHASE4, designInfo allocation: NON_RANDOMIZED, interventionModel: PARALLEL, interventionModelDescription: Phase IV, low-intervention clinical trial to develop prediction models that allow to determine the most appropriate therapeutic strategy in patients diagnosed with atopic dermatitis that need second-line systemic treatment., primaryPurpose: TREATMENT, maskingInfo masking: NONE, enrollmentInfo count: 150, type: ESTIMATED, armsInterventionsModule interventions name: Second-line systemic treatment, interventions name: Folllow-up of second-line systemic treatment already started, outcomesModule primaryOutcomes measure: Percentage of patients with primary non-response to second-line treatment., secondaryOutcomes measure: Percentage of patients achieving EASI-75, secondaryOutcomes measure: Time to treatment failure after week 16, secondaryOutcomes measure: Mean percentage of change in Eczema Area and Severity Index (EASI) score, secondaryOutcomes measure: Percentage of change in SCORAD (SCORing Atopic Dermatitis), secondaryOutcomes measure: Improvement of at least 75% in SCORAD (SCORing Atopic Dermatitis), secondaryOutcomes measure: Change of IGA (Investigator Global Assessment), secondaryOutcomes measure: Time to IGA score of 0/1 (Investigator Global Assessment), secondaryOutcomes measure: Change of BSA (Body surface area), secondaryOutcomes measure: Change in NRS, secondaryOutcomes measure: Change in RECAP, secondaryOutcomes measure: Percentage of patients having a variation of 4 points in their improvement in DLQI, secondaryOutcomes measure: Change in POEM (Patient-Oriented Eczema Measure), secondaryOutcomes measure: Rate of adverse events associated to second-line systemic treatment, secondaryOutcomes measure: Percentage of patients reaching EASI-90 (Percentage of patients reaching 90 percentage), eligibilityModule sex: ALL, stdAges: CHILD, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: Hospital La Paz, status: RECRUITING, city: Madrid, zip: 28046, country: Spain, contacts name: Irene García, MD, role: CONTACT, phone: +34-912071466, email: irene.ucicec@gmail.com, geoPoint lat: 40.4165, lon: -3.70256, hasResults: False
protocolSection identificationModule nctId: NCT06366919, orgStudyIdInfo id: DPT/Batch-Fall19/559, briefTitle: Comparison of Effectiveness of Alexander Technique Versus Feldenkrais Technique in Non - Specific Neck Pain Patients, statusModule overallStatus: ACTIVE_NOT_RECRUITING, startDateStruct date: 2024-04-01, primaryCompletionDateStruct date: 2024-05-15, completionDateStruct date: 2024-06-15, studyFirstPostDateStruct date: 2024-04-16, lastUpdatePostDateStruct date: 2024-04-16, sponsorCollaboratorsModule leadSponsor name: Superior University, class: OTHER, descriptionModule briefSummary: Comparison of Effectiveness of Alexander Technique Versus Feldenkrais Technique in Non - Specific Neck Pain Patients, conditionsModule conditions: Neck Pain, designModule studyType: INTERVENTIONAL, phases: NA, designInfo allocation: RANDOMIZED, interventionModel: PARALLEL, primaryPurpose: DIAGNOSTIC, maskingInfo masking: NONE, enrollmentInfo count: 44, type: ACTUAL, armsInterventionsModule interventions name: Alexander Technique (AT), interventions name: Feldenkrais Technique (FT), outcomesModule primaryOutcomes measure: Northwick Park Neck Pain Questionnaire, primaryOutcomes measure: REEDCO Posture Assessment and Sleep Quality Scale, eligibilityModule sex: ALL, minimumAge: 20 Years, maximumAge: 25 Years, stdAges: ADULT, contactsLocationsModule locations facility: Chaudary Muhammad Akram Teaching Hospital, Azra Naheed Medical College, Superior University, city: Lahore, state: Punjab, country: Pakistan, geoPoint lat: 31.558, lon: 74.35071, hasResults: False
protocolSection identificationModule nctId: NCT06366906, orgStudyIdInfo id: SYSKY-2023-426-01, briefTitle: 10-year Retrospective Study of Oral and Maxillofacial Squamous Cell Carcinoma, statusModule overallStatus: COMPLETED, startDateStruct date: 2023-05-10, primaryCompletionDateStruct date: 2024-02-10, completionDateStruct date: 2024-02-10, studyFirstPostDateStruct date: 2024-04-16, lastUpdatePostDateStruct date: 2024-04-16, sponsorCollaboratorsModule leadSponsor name: Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University, class: OTHER, descriptionModule briefSummary: Introduction: The incidence of occult cervical lymph node metastases (OCLNM) is reported to be 20%-30% in early-stage oral cancer and oropharyngeal cancer. There is a lack of an accurate diagnostic method to predict occult lymph node metastasis and to help surgeons make precise treatment decisions.Aim: To construct and evaluate a preoperative diagnostic method to predict occult lymph node metastasis (OCLNM) in early-stage oral and oropharyngeal squamous cell carcinoma (OC and OP SCC) based on deep learning features (DLFs) and radiomics features.Methods: A total of 319 patients diagnosed with early-stage OC or OP SCC were retrospectively enrolled and divided into training, test and external validation sets. Traditional radiomics features and DLFs were extracted from their MRI images. The least absolute shrinkage and selection operator (LASSO) analysis was employed to identify the most valuable features. Prediction models for OCLNM were developed using radiomics features and DLFs. The effectiveness of the models and their clinical applicability were evaluated using the area under the curve (AUC), decision curve analysis (DCA) and survival analysis., conditionsModule conditions: HNSCC, conditions: AI, conditions: Radiomic, conditions: MRI, designModule studyType: OBSERVATIONAL, designInfo observationalModel: CASE_CONTROL, timePerspective: RETROSPECTIVE, enrollmentInfo count: 319, type: ACTUAL, armsInterventionsModule interventions name: The Resnet50 deep learning (DL) model, outcomesModule primaryOutcomes measure: AUC(the area under the curve) values of the model, eligibilityModule sex: ALL, stdAges: CHILD, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: Sun yat-sen memorial hospital, city: Guangzhou, state: Guangdong, zip: 510000, country: China, geoPoint lat: 23.11667, lon: 113.25, locations facility: Sun yat-sun memorial hospital, city: Guangzhou, state: Guangdong, zip: 510000, country: China, geoPoint lat: 23.11667, lon: 113.25, hasResults: False
protocolSection identificationModule nctId: NCT06366893, orgStudyIdInfo id: PR(AG)297/2019, briefTitle: Enteral Supplementation With Docosahexaenoic Acid and Arachidonic Acid (DHA-AA) in Preterm Infants, statusModule overallStatus: RECRUITING, startDateStruct date: 2024-03-04, primaryCompletionDateStruct date: 2025-03-04, completionDateStruct date: 2025-03-04, studyFirstPostDateStruct date: 2024-04-16, lastUpdatePostDateStruct date: 2024-04-19, sponsorCollaboratorsModule leadSponsor name: Hospital Universitari Vall d'Hebron Research Institute, class: OTHER, descriptionModule briefSummary: Docosahexaenoic acid (DHA) and arachidonic acid (AA) have a critical effect on the health and neuronal development of the fetus and newborn. Their deficiency has been associated with increased neonatal morbidity, especially in preterm newborns at birth. Direct DHA supplementation during the first few weeks of life could prevent this deficiency.The aim is to increase DHA levels in the red blood cell membrane while maintaining the fetal proportion to AA in preterm infants through enteral administration of DHA/AA in a safe, tolerated, and effective manner. This approach aims to avoid the decline in DHA/AA levels and the consequences of their deficiency.The study is a single-center, prospective, randomized, controlled, open-label study involving preterm infants admitted to the Neonatology Department of Vall d'Hebron University Hospital in Barcelona., conditionsModule conditions: Infant, Premature, Diseases, designModule studyType: INTERVENTIONAL, phases: NA, designInfo allocation: RANDOMIZED, interventionModel: PARALLEL, primaryPurpose: PREVENTION, maskingInfo masking: NONE, enrollmentInfo count: 80, type: ESTIMATED, armsInterventionsModule interventions name: DHA/AA emulsion supplement for preterm infant, outcomesModule primaryOutcomes measure: Percentage comparison of erythrocyte membrane levels of DHA and AA, secondaryOutcomes measure: Tolerance of DHA emulsion administration, secondaryOutcomes measure: Compare the presence of pathologies in preterm infants between the supplemented group and the control group, eligibilityModule sex: ALL, maximumAge: 7 Days, stdAges: CHILD, contactsLocationsModule locations facility: Hospital Materno Infantil Vall d'Hebron, status: RECRUITING, city: Barcelona, zip: 08035, country: Spain, contacts name: Félix Castillo Salinas, Dr., role: CONTACT, phone: +34 934893899, email: felix.castillo@vallhebron.cat, contacts name: Félix Castillo Salinas, Dr., role: PRINCIPAL_INVESTIGATOR, geoPoint lat: 41.38879, lon: 2.15899, hasResults: False
protocolSection identificationModule nctId: NCT06366880, orgStudyIdInfo id: 2022.HPS.DI.434, briefTitle: Parenteral Nutrition Cycling for Prevention of Cholestatic Syndrome in Newborn, statusModule overallStatus: RECRUITING, startDateStruct date: 2024-03-11, primaryCompletionDateStruct date: 2024-12-15, completionDateStruct date: 2025-12-15, studyFirstPostDateStruct date: 2024-04-16, lastUpdatePostDateStruct date: 2024-04-16, sponsorCollaboratorsModule leadSponsor name: Hospital Pediátrico de Sinaloa, class: OTHER_GOV, descriptionModule briefSummary: Background: Despite the use of parenteral nutrition cycling (PNC) in neonatal intensive care units (NICU), there is limited evidence regarding the benefits in relation to the nutrición parenteral total (NPT) in term and late preterm infants.The recommendations from the recently published Latin American Society of Gastroenterology, Hepatology and Pediatric Nutrition guidelines are substantially different in this area, and surveys have reported variations in clinical practice.The aim of this randomised controlled trial (RCT) is to evaluate the benefits and risks of PNC AND parenteral nutrition total (NPT) in term and late preterm infants., conditionsModule conditions: Cholestasis in Newborn, designModule studyType: INTERVENTIONAL, phases: NA, designInfo allocation: RANDOMIZED, interventionModel: PARALLEL, primaryPurpose: PREVENTION, maskingInfo masking: SINGLE, whoMasked: OUTCOMES_ASSESSOR, enrollmentInfo count: 66, type: ESTIMATED, armsInterventionsModule interventions name: Parenteral nutrition cycling, outcomesModule primaryOutcomes measure: Incidence of cholestasis on Day 28 of admission., secondaryOutcomes measure: are total plasma bilirrubine profiles, secondaryOutcomes measure: the incidence of hypoglycaemia, eligibilityModule sex: ALL, minimumAge: 1 Hour, maximumAge: 28 Days, stdAges: CHILD, contactsLocationsModule locations facility: Hospital Pediatrico de Sinaloa, status: RECRUITING, city: Culiacán, state: Sinaloa, zip: 80200, country: Mexico, contacts name: Ana Karen Camargo Angulo, Dr., role: CONTACT, phone: 6681890586, phoneExt: +52, email: anakarencamargo96@gmail.com, geoPoint lat: 24.79032, lon: -107.38782, hasResults: False
protocolSection identificationModule nctId: NCT06366854, orgStudyIdInfo id: IRAS: 332418, briefTitle: UK ANDROMEDA-Shock-2 RCT, statusModule overallStatus: NOT_YET_RECRUITING, startDateStruct date: 2024-05-01, primaryCompletionDateStruct date: 2027-04-30, completionDateStruct date: 2028-04-30, studyFirstPostDateStruct date: 2024-04-16, lastUpdatePostDateStruct date: 2024-04-16, sponsorCollaboratorsModule leadSponsor name: Guy's and St Thomas' NHS Foundation Trust, class: OTHER, collaborators name: Pontificia Universidad Catolica de Chile, collaborators name: University of Rotterdam, The Netherlands, descriptionModule briefSummary: The purpose of the trial is to test if a strategy of resuscitation guided by capillary refill time and individualised clinical hemodynamic phenotyping can improve important clinical outcomes within 28 days in septic shock patients compared to usual care., conditionsModule conditions: Septic Shock, designModule studyType: INTERVENTIONAL, phases: NA, designInfo allocation: RANDOMIZED, interventionModel: PARALLEL, primaryPurpose: TREATMENT, maskingInfo masking: NONE, enrollmentInfo count: 25, type: ESTIMATED, armsInterventionsModule interventions name: Personalised fluid and haemodynamic resuscitation, outcomesModule primaryOutcomes measure: hospital mortality, primaryOutcomes measure: organ support, primaryOutcomes measure: length of stay, secondaryOutcomes measure: mortality, secondaryOutcomes measure: vital organ support, secondaryOutcomes measure: length of stay, eligibilityModule sex: ALL, minimumAge: 18 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule, hasResults: False
protocolSection identificationModule nctId: NCT06366815, orgStudyIdInfo id: 4619, briefTitle: phenotypeS in Non Ambulant Duchenne Muscular Dystrophy, acronym: GUP21003, statusModule overallStatus: RECRUITING, startDateStruct date: 2022-08-30, primaryCompletionDateStruct date: 2024-09-30, completionDateStruct date: 2025-12-30, studyFirstPostDateStruct date: 2024-04-16, lastUpdatePostDateStruct date: 2024-04-16, sponsorCollaboratorsModule leadSponsor name: Fondazione Policlinico Universitario Agostino Gemelli IRCCS, class: OTHER, descriptionModule briefSummary: The aims of the study are to prospectively collect information on several aspects of function in non-ambulant DMD patients by using a structured battery of tests including motor, respiratory and cardiac function, conditionsModule conditions: Duchenne Muscular Dystrophy, conditions: Natural History, conditions: Motor Function; Retardation, designModule studyType: OBSERVATIONAL, designInfo observationalModel: COHORT, timePerspective: PROSPECTIVE, enrollmentInfo count: 250, type: ESTIMATED, armsInterventionsModule interventions name: Different Phenotypes of non ambulant patients with Duchenne Muscular Dystrophy, outcomesModule primaryOutcomes measure: motor function, primaryOutcomes measure: respiratory function, primaryOutcomes measure: cardiac function, secondaryOutcomes measure: identify patterns of severity and of progression related to differnt genotypes, eligibilityModule sex: MALE, minimumAge: 8 Years, maximumAge: 35 Years, stdAges: CHILD, stdAges: ADULT, contactsLocationsModule locations facility: IRCCS catholic univeristy, status: RECRUITING, city: Roma, country: Italy, contacts name: Marika Pane, prof, role: CONTACT, phone: 0038063015, phoneExt: 6742, email: marika.pane@policlinicogemelli.it, contacts name: Daniela Leone, role: CONTACT, phone: 00390630158821, email: daniela.leone@policlinicogemelli.it, geoPoint lat: 41.89193, lon: 12.51133, hasResults: False
protocolSection identificationModule nctId: NCT06366802, orgStudyIdInfo id: Prognosis model-MM09, briefTitle: Cohort Construction and Prognostic Model Construction for Multiple Myeloma, statusModule overallStatus: ACTIVE_NOT_RECRUITING, startDateStruct date: 2022-05-03, primaryCompletionDateStruct date: 2027-05-02, completionDateStruct date: 2027-05-02, studyFirstPostDateStruct date: 2024-04-16, lastUpdatePostDateStruct date: 2024-04-16, sponsorCollaboratorsModule leadSponsor name: The First Affiliated Hospital of Soochow University, class: OTHER, descriptionModule briefSummary: Multiple myeloma (MM) is a disease caused by malignant plasma cell proliferation disorder. Survival outcomes continue to vary widely even within uniformly treated clinical trial populations. How to construct a clinical prognosis model of MM through real-world data to guide the selection of treatment options, standardize patient management, and improve survival expectations, is a major problem that needs to be solved urgently. It is necessary to build an MM-specific cohort in China to comprehensively understand the characteristics of MM patients, explore treatment options, and improve prognostic factors for survival outcomes., conditionsModule conditions: Multiple Myeloma, designModule studyType: OBSERVATIONAL, designInfo observationalModel: COHORT, timePerspective: RETROSPECTIVE, enrollmentInfo count: 1000, type: ESTIMATED, outcomesModule primaryOutcomes measure: Overall survival, secondaryOutcomes measure: Progression free survival(PFS), eligibilityModule sex: ALL, stdAges: CHILD, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: The First Affiliated Hospital of Soochow University, city: Suzhou, state: Jiangsu, zip: 215006, country: China, geoPoint lat: 31.30408, lon: 120.59538, hasResults: False
protocolSection identificationModule nctId: NCT06366789, orgStudyIdInfo id: ZE46-0134-0002, secondaryIdInfos id: CT-2024-CTN-00161-1, type: OTHER, domain: Therapeutic Goods Administration, briefTitle: Dose Escalation and Expansion Study to Evaluate the Safety, PK, PD and Efficacy of ZE46-0134 in Adults With FLT3 Mutated Relapsed or Refractory Acute Myeloid Leukemia, statusModule overallStatus: NOT_YET_RECRUITING, startDateStruct date: 2024-04, primaryCompletionDateStruct date: 2025-09, completionDateStruct date: 2027-12, studyFirstPostDateStruct date: 2024-04-16, lastUpdatePostDateStruct date: 2024-04-16, sponsorCollaboratorsModule leadSponsor name: Eilean Therapeutics, class: INDUSTRY, descriptionModule briefSummary: This is a clinical study aiming to assess pharmacokinetics, pharmacodynamics and preliminary efficacy of ZE46-0134 in patients with FLT3 mutated Relapsed or Refractory Acute Myeloid Leukemia, conditionsModule conditions: AML With Gene Mutations, designModule studyType: INTERVENTIONAL, phases: PHASE1, designInfo allocation: NON_RANDOMIZED, interventionModel: SEQUENTIAL, interventionModelDescription: dose escalation and dose optimization study, primaryPurpose: TREATMENT, maskingInfo masking: NONE, enrollmentInfo count: 60, type: ESTIMATED, armsInterventionsModule interventions name: ZE46-0134, outcomesModule primaryOutcomes measure: The incidence of DLTs, secondaryOutcomes measure: Incidence of AE/SAE, secondaryOutcomes measure: Incidence of clinically significant abnormal laboratory results, secondaryOutcomes measure: Incidence of abnormal clinically significant ECG results, secondaryOutcomes measure: Number of patients with AEs of Grade ≥ 3, secondaryOutcomes measure: Number of treatment-related deaths, secondaryOutcomes measure: Plasma Cmax, secondaryOutcomes measure: Plasma Css, secondaryOutcomes measure: Plasma Cmin, secondaryOutcomes measure: Plasma AUC, secondaryOutcomes measure: Number of patients attaining any type of Complete Remission (CR, CRh, CRi) by Cycle 6, secondaryOutcomes measure: Number of patients attaining CR by Cycle 6, secondaryOutcomes measure: Number of patients attaining response (CR, CRh, CRi, MLFS) by Cycle 6, otherOutcomes measure: Proportion of patients who became FLT3 ITD and TKD undetectable, otherOutcomes measure: Number of patients with Genomic or proteomic abnormalities, eligibilityModule sex: ALL, minimumAge: 18 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: Linear Clinical Research Ltd, city: Perth, state: Nedlands, WA, zip: 6009, country: Australia, contacts name: Carolyn Grove, Prof, role: CONTACT, geoPoint lat: -31.95224, lon: 115.8614, hasResults: False
protocolSection identificationModule nctId: NCT06366776, orgStudyIdInfo id: 23-278, briefTitle: Emulated Study of Vitamin D Correction vs Non-Correction, statusModule overallStatus: NOT_YET_RECRUITING, startDateStruct date: 2024-04, primaryCompletionDateStruct date: 2024-06, completionDateStruct date: 2024-12, studyFirstPostDateStruct date: 2024-04-16, lastUpdatePostDateStruct date: 2024-04-16, sponsorCollaboratorsModule leadSponsor name: The Cooper Health System, class: OTHER, collaborators name: Won Sook Chung Foundation, descriptionModule briefSummary: * This is a single-site retrospective electronic chart review of Cooper Health System Inpatients and Outpatients from 2008 through 2023 aged eighteen years or older. This review is designed as an emulation of a randomized clinical trial with a nonrandomized database.* The primary objectives are to compare healthcare costs and healthcare utilization between subjects who have corrected low vitamin D levels and those without corrected low vitamin D levels., conditionsModule conditions: Vitamin D Deficiency, designModule studyType: OBSERVATIONAL, designInfo observationalModel: COHORT, timePerspective: RETROSPECTIVE, enrollmentInfo count: 9000, type: ESTIMATED, armsInterventionsModule, outcomesModule primaryOutcomes measure: Ten healthcare costs parameters among the corrected Treatment Group and the uncorrected Control Group A., primaryOutcomes measure: Ten healthcare utilization parameters among the corrected Treatment Group and the uncorrected Control Group A., secondaryOutcomes measure: Ten healthcare costs parameters among patients with sufficient vitamin D levels (Control Group B)., secondaryOutcomes measure: Ten healthcare utilization parameters among patients with sufficient vitamin D levels (Control Group B)., eligibilityModule sex: ALL, minimumAge: 18 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule, hasResults: False